Yardeni Research Sees Summer Market Volatility Before Rally Resumes
Yardeni Research anticipates a period of market choppiness driven by geopolitical, trade, and AI-related risks, but maintains its bullish year-end S&P 500 forecast of 8,250.
Latest by Marcus Chen
CVS Group Shares Slide After Like-for-Like Sales Miss Corporate Targets
Shares in UK veterinary services provider CVS Group Plc fell after its full-year trading update revealed like-for-like sales growth of just 2.1%, well below the company's medium-term guidance.
STMicroelectronics' Weak Forecast Triggers European Chip Sector Sell-Off
Shares of STMicroelectronics plunged after the company issued a third-quarter revenue forecast that missed analyst expectations, creating a ripple effect that pulled down other major European semiconductor stocks.
Segro Shares Surge as Board Signals Support for Revised £14 Billion Prologis Bid
Shares in UK warehouse giant Segro jumped over 7% after its board announced it would recommend a revised £14 billion takeover proposal from US rival Prologis, marking a major breakthrough in the acquisition talks.
TotalEnergies Stock Surges on Strongest Quarterly Profit in Nearly Three Years
Shares in the French energy major climbed after it reported a 67% year-over-year jump in Q2 adjusted net income, driven by soaring oil prices and prompting a dividend increase.
Soitec Shares Surge Over 20% on Strong AI-Driven Revenue Beat and Raised Outlook
The French semiconductor materials supplier's stock jumped after it reported a significant first-quarter revenue beat, driven by a doubling of sales in its AI-focused Photonics-SOI division, and raised its full-year forecast for the segment.
Ipsos Shares Climb on First-Half Earnings Beat and Confirmed Margin Guidance
The French market research firm reported H1 EBIT that topped analyst forecasts by 4% and reaffirmed its full-year profitability targets, boosting investor confidence despite a slight trim to its sales growth outlook.
SpaceX Stock Hits New Low as $123 Billion Lockup Expiry Looms
Shares of SpaceX have fallen to a 52-week low, trading significantly below their IPO price as investors brace for a massive $123 billion share lockup expiry in early August and weigh long-term growth prospects against near-term pressures.
Alligator Bioscience Stock Plummets 73% After Halting Lead Cancer Drug Development
The Swedish biotech firm's shares collapsed after it discontinued independent development of its cornerstone drug candidate, mitazalimab, and announced a highly dilutive capital raise to fund operations.